Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam and Benitec Exchange Licensing Rights for RNAi Technologies

NEW YORK, April 13 (GenomeWeb News) - Alnylam Pharmaceuticals and Benitec have exchanged licensing options for RNA interference intellectual property, the companies said yesterday.

 

Under the agreement, Benitec and its licensees have the option to non-exclusively license expressed RNAi technology from Alnylam. Benitec also has the right to obtain up to five exclusive InterfeRx licenses from Alnylam to develop synthetic RNAi therapeutics against specific targets.

 

Alnylam has the option to non-exclusively license technology covering expressed RNAi and synthetic siRNAs from Benitec.

 

If either company exercises its options, the other company will receive license fees and be eligible for milestone payments and royalties on any products developed under the licenses.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.